

Electronic Report to the Board

Report of the Secretariat's Grant Approvals Committee

GF/B49/ER03

Board Decision

Purpose of the paper: This document proposes the decision points as follows:

1. GF/B49/EDP03: Decision on the Secretariat's Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2020-2022 Allocation Period ¹

Document Classification: Internal.

Document Circulation: Board Members, Alternate Board Members, Constituency Focal Points and Committee Members.

This document may be shared by the Focal Points within their respective Board constituency. The document must not however be subject to any further circulation or otherwise be made public.

¹ The Secretariat recommends the approval of **US\$2,000,000** of additional funding representing a private sector contribution to be integrated into the Nigeria HIV grant.

Decision

Decision Point: GF/B49/EDP03: Decision on the Secretariat's Recommendation on Funding Unfunded Quality Demand from the 2020-2022 Allocation Period

The Board:

1. Approves the revised budget recommended for the grant listed in Table 1 of GF/B49/ER03 ("Table 1");
2. Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, and (b) is subject to the availability of funding; and
3. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

This decision does not have material budgetary implications for operating expenses.

Executive Summary

Context and Input Received

Secretariat's Recommendation on Additional Funding

The Secretariat hereby recommends the approval of:

- **US\$2,000,000** of additional funding representing a private sector contribution to be integrated into the 2020-2022 allocation period Nigeria HIV grant set out at Table 1.
- All relevant documents containing the Secretariat's reasons for its recommendations to the Board have been made available on the Governance Extranet and are accessible through [this link](#).

Input Sought

The Board is requested to review the request and agree on a 'no objection' basis, the decision point GF/B49/EDP03: Decision on the Secretariat's Recommendation on Additional Funding to Finance Unfunded Quality Demand from the 2020-2022 Allocation Period.

Table 1: Secretariat's Recommendation on Additional Funding to Finance UQD from the 2020-2022 Allocation Period

Please note that each country name is [linked](#) to the extranet site where supporting documents are available for review.

N	Applicant	Disease Component	Grant Name	Additional Funding Source	Currency	Previously Approved Program Budget	Recommended Additional Funding	Revised Program Budget
1	Nigeria	HIV/AIDS	NGA-H-FHI360	Private sector	US\$	290,478,305	2,000,000	292,478,305

Summary of the Deliberations of the Secretariat's Grant Approvals Committee (GAC) on Funding Recommendations

A private sector contribution of US\$14.5 million was made available for HIV Self-Testing Matching Funds (HIV ST MF) for the 2020-2022 funding cycle, subject to access and programmatic conditions communicated in relevant countries' allocation letters. Since performance-based targets have been achieved during the course of implementation, this private sector donor has agreed to contribute an additional US\$10 million to cover technical assistance and programmatic needs related to HIV self-testing as set out in the UQD of the following portfolios: Malawi, Nigeria, Uganda and Zambia.

In this report, the Secretariat recommends to the Board an additional funding revision for the Nigeria (NGA-H-FHI360) grant. The additional funding revisions for the remaining portfolios will be submitted for Board consideration in due course.

1.1 Nigeria HIV: Family Health International (NGA-H-FHI360)

Nigeria has a mixed HIV epidemic, with a national prevalence of 1.3 percent among the general population, and up to 4 percent in high-burden states in 2018. Prevalence rates among key populations and other vulnerable groups, where data is available, is notably higher, reaching up to 29 percent among transgender individuals in 2020. The primary objective of the HIV grant is to reduce the incidence of new HIV infections, mortality, and morbidity in Nigeria, including key and vulnerable populations.

The proposed additional funding from a private sector contribution will support expanding HIV self-testing in Nigeria. The country was selected for the additional funds based on: (i) achieving the proportion of the performance targets per country at 45 percent or more, (ii) having ambitious plans for scaling up HIV testing, and (iii) utilizing innovative testing approaches, including testing among key populations and the use of a diversified pool of HIV self-testing kits including oral fluid and blood-based products that ensures efficiencies in costing and access for the users.

Nigeria's HIV program has effectively implemented HIV self-testing interventions through multiple delivery channels, including one-stop shops, peer networks, and community hotspots. From January 2021 to March 2023, a total of 533,378 HIV self-testing kits were distributed targeting priority populations. Notably, the confirmation rate for HIV-positive test results within this period stood at 93 percent, while 99.5 percent of individuals who tested positive were successfully linked to antiretroviral therapy initiation.

This additional investment will procure 677,200 HIV self-test kits, as well as cover associated supply management costs. The investment will address program

implementation gaps and ensure an adequate supply of HIV self-testing commodities during the transition between Grant Cycle 6 and Grant Cycle 7. All commodities will be procured through the Global Fund's Pooled Procurement Mechanism. Existing in-country storage and distribution arrangements will remain unchanged.

2.1 Of the applicants for which funding recommendations are currently being made, Nigeria has not signed or ratified the Global Fund Agreement on Privileges and Immunities.

Document Classification: Internal.

Document Circulation: Board Members, Alternate Board Members, Constituency Focal Points and Committee Members.

This document may be shared by the Focal Points within their respective Board constituency. The document must not however be subject to any further circulation or otherwise be made public.

Annex 1 – Relevant Past Decisions

Pursuant to the Governance Plan for Impact as approved at the Thirty-Second Board Meeting,² the following summary of relevant past decision points is submitted to contextualize the decision points proposed in Section I above.

Relevant past Decision Point	Summary and Impact
GF/B44/EDP08: Decision on the Secretariat's recommendation on Funding from the 2020-2022 Allocation	This decision point approved the Nigeria HIV grant (NGA-H-FHI360)

² GF/B32/DP05: Approval of the Governance Plan for Impact as set forth in document GF/B32/08 Revision 2 (<http://www.theglobalfund.org/Knowledge/Decisions/GF/B32/DP05/>)